Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:1816
SEHK:1816Renewable Energy

CGN Power (SEHK:1816) Valuation Check As Bond Conversion To A Shares Nears In 2026

CGN Power (SEHK:1816) has said its A Share Convertible Corporate Bonds will become eligible for conversion into A shares on January 15, 2026, a move that could reshape capital structure and liquidity. See our latest analysis for CGN Power. At the current share price of HK$3.12, CGN Power’s recent 7-day and 30-day share price returns of 4.0% and 6.48% suggest interest is picking up again. Its 1-year and 5-year total shareholder returns of 28.91% and 112.95% show a longer track record that...
SEHK:4
SEHK:4Real Estate

A Look At Wharf Holdings (SEHK:4) Valuation After Citi’s Sell Rating On Hong Kong Property Stocks

Analyst downgrade puts Wharf (Holdings) (SEHK:4) back in focus Citi’s latest report on Hong Kong real estate stocks, including a Sell call on Wharf (Holdings) (SEHK:4), has drawn attention to short selling activity and the stock’s discount to net asset value. See our latest analysis for Wharf (Holdings). Wharf (Holdings)’ share price has been relatively steady around HK$23.02, with a 7 day share price return of 4.07% and a 90 day share price return of 6.08%. Its 1 year total shareholder...
TSX:PET
TSX:PETSpecialty Retail

A Look At Pet Valu Holdings (TSX:PET) Valuation After Recent Board And Governance Changes

Pet Valu Holdings (TSX:PET) is drawing attention after announcing board changes that bring veteran retail and finance executives Carmen Fortino and Matt Reindel onto the board, replacing nominees of former principal shareholders. See our latest analysis for Pet Valu Holdings. The governance shake up arrives after a mixed run for investors, with a 1 year total shareholder return of 9.66%, a 3 year total shareholder return of 23.57%, and a recent 90 day share price decline of 17.82% from the...
NasdaqGS:ANDE
NasdaqGS:ANDEConsumer Retailing

Is Andersons (ANDE) Quietly Rewriting Its Renewables Strategy With A Higher ROCE?

Recently, Andersons has increased its earnings before interest and tax while keeping capital employed broadly unchanged, lifting its return on capital employed to 5.4% from prior losses. This shift suggests Andersons is extracting more profit from its existing asset base, raising questions about how it will reinvest to sustain these improved returns. We’ll now explore how Andersons’ improved return on capital employed may influence its existing investment narrative built around renewables...
TSX:BLX
TSX:BLXRenewable Energy

Assessing Boralex’s (TSX:BLX) Valuation As Sanjgon Battery Storage Comes Online In North America

Boralex (TSX:BLX) has commissioned the 80 MW / 320 MWh Sanjgon Battery Energy Storage facility in Ontario, its first operational storage project in North America, in partnership with Walpole Island First Nation. See our latest analysis for Boralex. Boralex’s commissioning of Sanjgon comes after a mixed year for the stock, with a 30 day share price return of 6.32% but a 3 year total shareholder return of 30.81% decline. This suggests momentum has recently improved while longer term returns...
NasdaqGS:SYRE
NasdaqGS:SYREBiotechs

Spyre Therapeutics (SYRE) Valuation After New Trial Milestones And Commercial Leadership Appointment

Spyre Therapeutics (SYRE) is back on investor radar after management outlined six planned proof of concept readouts for 2026 and reported faster enrollment in its SKYLINE ulcerative colitis trial, alongside appointing experienced commercial leader Kate Tansey Chevlen as CCO. See our latest analysis for Spyre Therapeutics. The share price has reacted quickly to the clinical and leadership updates, with a 1-day share price return of 7.15% and a 90-day share price return of 47.81%. The 1-year...
XTRA:EVT
XTRA:EVTLife Sciences

Evotec (XTRA:EVT) Is Up 17.3% After Landing €250m Sanofi Alliance And IR Overhaul – Has The Bull Case Changed?

Evotec SE recently entered a five-year multi-component alliance with Sanofi, featuring a minimum guaranteed commitment of €250 million and an upfront payment of more than €40 million, while also appointing Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations to integrate its communications and investor outreach. The combination of a large, multi-year Sanofi commitment across Evotec’s Execute and Innovate segments and a strengthened investor...
NYSE:ALG
NYSE:ALGMachinery

What Alamo Group (ALG)'s Higher Quarterly Dividend Says About Its Capital Return Priorities

Alamo Group Inc. recently announced that its Board of Directors raised the quarterly dividend to US$0.34 per share, an increase of US$0.04, with the January payout made on January 29, 2026 to shareholders of record as of January 16, 2026. This higher dividend underscores management’s emphasis on returning cash to shareholders and may be viewed as an indication of financial resilience. We’ll now examine how this higher quarterly dividend and cash-return focus feeds into Alamo Group’s existing...
NYSE:R
NYSE:RTransportation

How Investors May Respond To Ryder System (R) After Wolfe Research’s Downgrade To Peer Perform

On January 8, 2026, Wolfe Research downgraded Ryder System from an “Outperform” rating to “Peer Perform,” while maintaining its existing view on the company. The downgrade, coming from an analyst with a relatively strong track record, adds a fresh layer of scrutiny to Ryder’s longer-term logistics and contract-based growth story. We’ll now examine how Wolfe Research’s downgrade and its implications for analyst sentiment may influence Ryder System’s existing investment narrative. These 18...
NasdaqGS:OPCH
NasdaqGS:OPCHHealthcare

Is Option Care’s Expanded US$1 Billion Buyback Altering The Investment Case For Option Care Health (OPCH)?

Option Care Health, Inc., the largest independent provider of home and alternate site infusion services in the U.S., recently released preliminary unaudited results for the fourth quarter and full year 2025, issued initial 2026 guidance calling for net revenue of US$5.8 billion to US$6.0 billion, and doubled its share repurchase authorization to US$1.0 billion. This combination of early guidance and a larger buyback authorization highlights management’s confidence in the business model and...
LSE:TRI
LSE:TRIMachinery

3 UK Penny Stocks With Market Caps Under £100M

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index experiencing a decline due to weak trade data from China, highlighting global economic uncertainties. Despite these broader market fluctuations, penny stocks continue to attract investors seeking potential growth opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, it remains relevant for those looking to explore investments that combine financial stability with...
NYSE:TIC
NYSE:TICProfessional Services

Is JPMorgan’s Overweight on TIC Solutions (TIC) a Real Endorsement of Its Integration Strategy?

JPMorgan recently initiated coverage on TIC Solutions with an Overweight rating, citing the company’s technical depth, operational discipline, and progress integrating Acuren and NV5, including identified cost synergies and cross-selling opportunities. This endorsement highlights how integration-driven efficiency gains and broader service optionality are becoming central to the investment case for TIC Solutions. Next, we will examine how JPMorgan’s focus on integration synergies and...
NYSE:GRDN
NYSE:GRDNHealthcare

Insider Buying And Ownership Concentration Prompt Fresh Look At Guardian Pharmacy Services (GRDN) Valuation

Insider buying and concentrated ownership draw attention to Guardian Pharmacy Services (GRDN) Recent insider buying at Guardian Pharmacy Services (GRDN), combined with institutional investors holding 35% of the stock and five shareholders controlling 52%, is drawing fresh attention to who really drives decisions at the company. See our latest analysis for Guardian Pharmacy Services. At a share price of $31.51, Guardian Pharmacy Services has seen a 29.03% 90 day share price return and a 49.83%...